The British Journal of Psychiatry (2008) 192: 338-343. doi: 10.1192/bjp.bp.107.037101
© 2008 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Oberlander, T. F.
Right arrow Articles by Hertzman, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oberlander, T. F.
Right arrow Articles by Hertzman, C.

Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study

Tim F. Oberlander, MD

Department of Pediatrics and Human Early Learning Partnership

William Warburton, PhD

Human Early Learning Partnership

Shaila Misri, MD, FRCPC

Department of Psychiatry

Jaafar Aghajanian, BSc and Clyde Hertzman, MD

Human Early Learning Partnership, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence: Dr Tim F. Oberlander, Early Human Experience Unit, Centre for Community Child Health Research, Room L408, 4480 Oak Street, Vancouver, BC V6 3V4, Canada. E-mail: toberlander{at}cw.bc.ca

Declaration of interest

None.

Background

Late-gestational serotonin reuptake inhibitor (SRI) exposure has been linked to adverse neonatal outcomes; however, the impact of timing and duration of exposure is unknown.

Aims

To determine whether late-gestational exposure to an SRI is associated with increased risk of adverse neonatal outcome relative to early exposure.

Method

Population-based maternal and neonatal health records were linked to prenatal maternal prescription records for an SRI medication (n=3500).

Results

After controlling for maternal illness and duration of exposure, using propensity score matching, neonatal outcomes did not differ between late and early exposure (P>0.05). After controlling for maternal illness, longer prenatal exposure increased the risks of lower birth weight, respiratory distress and reduced gestational age (P<0.05).

Conclusions

Using population health data, length of gestational SRI exposure, rather than timing, increased the risk for neonatal respiratory distress, lower birth weight and reduced gestational age, even when controlling for maternal illness and medication dose. These findings highlight the importance of distinguishing the specific impact of medication exposure from exposure to maternal illness itself.


Related articles in BJP:

From the Editor’s desk
Peter Tyrer
BJP 2008 192: 400. [Full Text]  

Highlights of this issue
Sukhwinder S. Shergill
BJP 2008 192: A18. [Full Text]  



This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
K. A. Yonkers
Parsing Risk for the Use of Selective Serotonin Reuptake Inhibitors in Pregnancy
Am J Psychiatry, March 1, 2009; 166(3): 268 - 270.
[Full Text] [PDF]

Home page
 JWatch PsychiatryHome page
Emerging Perspectives: Psychotropic Drugs During Pregnancy -- New Data on Neonatal Outcomes
Journal Watch Psychiatry, July 14, 2008; 2008(714): 1 - 1.
[Full Text]

Home page
 Br. J. PsychiatryHome page
C. Paton
Prescribing in pregnancy
The British Journal of Psychiatry, May 1, 2008; 192(5): 321 - 322.
[Abstract] [Full Text] [PDF]